Astaxanthin attenuates hepatic damage and mitochondrial dysfunction in non-alcoholic fatty liver disease by up-regulating the FGF21/PGC-1 alpha pathway
机构：[1]Department of Gastroenterology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China[2]Department of Gastroenterology, Shidong Hospital of Shanghai, Shanghai, China[3]Department of Gastroenterology, Putuo People's Hospital, Tongji University School of Medicine, Shanghai, China[4]Shanghai Tenth Hospital, School of Clinical Medicine of Nanjing Medical University, Shanghai, China[5]Department of Gastroenterology, Zhongshan Hospital of Fudan University, Shanghai, China[6]Shanghai Institute of Liver Diseases, Zhongshan Hospital of Fudan University, Shanghai, China[7]Shanghai Tongren Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China[8]Department of Gastroenterology, Shanghai First People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
Background and Purpose Non-alcoholic fatty liver disease (NAFLD) is considered to be one of the most common chronic liver diseases across worldwide. Astaxanthin (Ax) is a carotenoid, and beneficial effects of astaxanthin, including anti-oxidative, anti-inflammatory, and anti-tumour activity, have been identified. The present study aimed to elucidate the protective effect of astaxanthin against NAFLD and its underlying mechanism. Experimental Approach Mice were fed either a high fat or chow diet, with or without astaxanthin, for up to 12 weeks. L02 cells were treated with free fatty acids combined with different doses of astaxanthin for 48 h. Histopathology, expression of lipid metabolism, inflammation, apoptosis, and fibrosis-related gene expression were assessed. And the function of mitochondria was also evaluated. Key Results The results indicated that astaxanthin attenuated HFD- and FFA-induced lipid accumulation and its associated oxidative stress, cell apoptosis, inflammation, and fibrosis both in vivo and in vitro. Astaxanthin up-regulated FGF21 and PGC-1 alpha expression in damaged hepatocytes, which suggested an unrecognized mechanism of astaxanthin on ameliorating NAFLD. Conclusion and Implications Astaxanthin attenuated hepatocyte damage and mitochondrial dysfunction in NAFLD by up-regulating FGF21/PGC-1 alpha pathway. Our results suggest that astaxanthin may become a promising drug to treat or relieve NAFLD.
基金：
the Health System Innovation Plan of Shanghai
Putuo District Science and Technology
Committee, Grant/Award Number:
PTKWWS2018001; the Project of Shanghai
Health Commission, Grant/Award Number:
2019469; the WBN Liver Disease Research
Fund of China Hepatitis Prevention
Foundation, Grant/Award Number:
CFHPC2019031; theYangfan Plan of Shanghai
Science and Technology Commission, Grant/
Award Number: 2018YF1420000; Project of
Shanghai Health Commission, Grant/Award
Number: 2019469; Yangfan Plan of Shanghai Science and Technology Commission, Grant/
Award Number: 2018YF1420000; WBN Liver
Disease Research Fund of China Hepatitis
Prevention Foundation, Grant/Award Number:
CFHPC2019031; Health System Innovation
Plan of Shanghai Putuo District Science and
Technology Committee, Grant/Award Number:
PTKWWS2018001; National Natural Science
Foundation of Shanghai, Grant/Award
Number: 19ZR1447700; National Natural
Science Foundation of China, Grant/Award
Numbers: 81670472, 81700502, 81800538
第一作者机构：[1]Department of Gastroenterology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China
共同第一作者：
通讯作者：
通讯机构：[1]Department of Gastroenterology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai, China[8]Department of Gastroenterology, Shanghai First People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China[*1]Department of Gastroenterology, Shanghai Tenth People's Hospital, Tongji University School of Medicine, Shanghai 200072, China.[*2]Department of Gastroenterology, Zhongshan Hospital of Fudan University, Shanghai 200032, China[*3]Shanghai Institute of Liver Diseases, Zhongshan Hospital of Fudan University, Shanghai, 200032, China.
推荐引用方式(GB/T 7714)：
Wu Liwei,Mo Wenhui,Feng Jiao,et al.Astaxanthin attenuates hepatic damage and mitochondrial dysfunction in non-alcoholic fatty liver disease by up-regulating the FGF21/PGC-1 alpha pathway[J].BRITISH JOURNAL OF PHARMACOLOGY.2020,177(16):3760-3777.doi:10.1111/bph.15099.
APA：
Wu, Liwei,Mo, Wenhui,Feng, Jiao,Li, Jingjing,Yu, Qiang...&Guo, Chuanyong.(2020).Astaxanthin attenuates hepatic damage and mitochondrial dysfunction in non-alcoholic fatty liver disease by up-regulating the FGF21/PGC-1 alpha pathway.BRITISH JOURNAL OF PHARMACOLOGY,177,(16)
MLA：
Wu, Liwei,et al."Astaxanthin attenuates hepatic damage and mitochondrial dysfunction in non-alcoholic fatty liver disease by up-regulating the FGF21/PGC-1 alpha pathway".BRITISH JOURNAL OF PHARMACOLOGY 177..16(2020):3760-3777
医学